Ute Dugan

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Lacey Padrón, Deena M. Maurer, Mark H. O’Hara et al. · Nature Medicine · 2022 · 350 citations · Full text

Medicine, Oncology, Pharmacology +15

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Mark H. O’Hara, Eileen M. O’Reilly, Gauri R. Varadhachary et al. · The Lancet Oncology · 2020 · 301 citations

Medicine, Oncology, Pharmacology +15

From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients

H‐G Eichler, LG Baird, Richard Barker et al. · Clinical Pharmacology & Therapeutics · 2015 · 187 citations · Full text

Pharmacy, Pharmaceutical Policy, Drug Approval Processes +15

Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer

Tiffany A. Traina, Maria Theodoulou, Kimberly Feigin et al. · Journal of Clinical Oncology · 2008 · 72 citations

Medicine, Oncology, Pharmacology +17

Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients

Mark H. O’Hara, Eileen M. O’Reilly, Rosemarie Mick et al. · Cancer Research · 2019 · 65 citations

Medicine, Oncology, Pharmacology +17